News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HENGRUI PHARMA Reaches Exclusive License Agreement with GSK w/ Potential Milestone Amt USD12B
HENGRUI PHARMA (01276.HK) announced the signing of strategic cooperation agreements with GSK, granting GSK an exclusive worldwide right excluding Mainland China, Hong Kong, Macau a...
Reset
Send
The window will close in 5 seconds
HENGRUI PHARMA Reaches Exclusive License Agreement with GSK w/ Potential Milestone Amt USD12B
Close
Recommend
5
Positive
6
Negative
3
 
SHORT SELL
 
STOCK INFO

HENGRUI PHARMA (01276.HK)  -3.750 (-4.756%)   announced the signing of strategic cooperation agreements with GSK, granting GSK an exclusive worldwide right excluding Mainland China, Hong Kong, Macau and Taiwan, to its innovative drug PDE3/4 inhibitor HRS-9821 for the treatment of chronic obstructive pulmonary disease (COPD), as well as options for up to 11 early-stage programs in oncology, respiratory and immunology fields.

Pursuant to the agreement, HENGRUI PHARMA will receive an upfront payment of US$500 million. If all programs are successfully developed and commercialized, the potential total amount could reach approximately US$12 billion, along with tiered royalties on global product net sales.
(HK stocks quote is delayed for at least 15 mins.)

Related NewsG Sachs: Easing CN-US Trade Tensions/ Other Factors Boost A-shr Indices to New Highs; MSCI China Index Target Raised to 90

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.